Intelligence Ventures

Intelligence Ventures Research Document Investment Thesis & Fund Overview Intelligence Ventures is an early-stage venture capital fund dedicated exclusively to the intersection of Artificial Intelligence and Healthcare. The fund was founded in December 2022 by Doug Nissinoff, who conducted deep market research recognizing a massive opportunity in AI-driven healthcare solutions. Nissinoff's research revealed that Moore's Law continued holding with computational power doubling every two years, ChatGPT reached 100 million users in early 2023, and the AI healthcare market was growing at a remarkable 36.83% compound annual growth rate, projected to reach $613.81B by 2034. This convergence of technological advancement and market opportunity convinced Nissinoff to build Intelligence Ventures with unwavering conviction despite facing significant headwinds during the fund's formation period. Investment Criteria & Strategic Focus Intelligence Ventures maintains a highly disciplined investment approach focusing on four specific healthcare verticals where AI can serve as a core, defensible competitive advantage. The fund explicitly does NOT invest in drug development itself but rather in the tools and technologies that enable drug discovery and development. The four verticals are: (1) Biotech and Pharma Tools—AI-powered platforms accelerating drug research and optimization; (2) Medical Devices—hardware solutions with integrated AI featuring clear pathways to accelerated regulatory approval; (3) Diagnostics—rapid, scalable, cost-effective diagnostic solutions leveraging AI and machine learning; and (4) Healthcare SaaS—data-driven software platforms utilizing AI to improve clinical workflows, enhance patient outcomes, and optimize operational efficiency. Each vertical represents a multi-billion dollar market opportunity with AI serving as the irreplaceable core technology. Stage Focus & Geographic Requirements Intelligence Ventures targets pre-seed and seed-stage companies, defining this stage as the first dilutive round of capital from institutional investors. The fund makes initial checks of $50,000 to help companies progress toward product-market fit and subsequent funding rounds. A critical requirement is geographic: the fund ONLY invests in US and Canada-based companies with established operational corporations and team members physically present in either country. The fund explicitly does not fund companies merely planning to establish operations; companies must already be operational. This requirement ensures founders have committed to the North American market with boots on the ground. Recent Investments & Portfolio Activity Intelligence Ventures announced two groundbreaking first investments demonstrating their thesis in action. Investment number one was AGED Diagnostics, an AI-driven blood test platform addressing nonalcoholic steatohepatitis (NASH), a silent epidemic affecting millions globally. Led by CEO Rachel Zayas-Schwartz, AGED Diagnostics was perfectly positioned following the FDA's March 2024 approval of Rezdiffra, the first-ever treatment for NASH with fibrosis—suddenly creating massive diagnostic demand. Investment number two was HEARTio, an AI platform revolutionizing coronary artery disease diagnosis using 12-lead electrocardiograms. Founded by Utkars Jain and Michael Leasure, HEARTio leverages a proprietary dataset of 16+ million ECGs and has earned FDA Breakthrough Device designation, indicating the agency's recognition of its innovation potential. Beyond these two anchor investments, the fund's Q3 2025 Virtual HealthAI Pitch Showcase selected seven exceptional companies from eighty-two applications. These portfolio companies include Morph Labs (brain-controlled prosthetics requiring no surgery), Xander (augmented reality glasses enabling real-time conversation visualization), Elnora AI (transforming failed laboratory experiments into drug discovery breakthroughs), Nakya (AI platform consolidating five or more lab management tools), UBiosis Health (autonomous AI nurse improving patient outcomes five times over), VizBriz Technologies (AI-powered sleep apnea screening and treatment planning), plus one unrevealed first investment officially announced at the showcase event. Team Composition & Fund Infrastructure The Intelligence Ventures team brings deep healthcare and technology expertise. Doug Nissinoff serves as founder and managing partner, driving overall strategy and investor relations. Gavin Hirst brings partner-level expertise specifically in small molecule drug discovery and biotech applications of AI. William (KC) Collins, MD, MBA, provides critical clinical and medical domain knowledge as a partner. Steven M. Gottlieb, MD, serves as medical advisor offering clinical perspective. Jonathan Mengel completes the core team. The fund has successfully closed with thirteen limited partners onboard and expects five to ten additional LP commitments before year-end. The pipeline remains robust with over four hundred startup applications received to date and five to fifteen new applications arriving weekly, demonstrating strong founder interest in the AI healthcare space. Fund Philosophy & Investment Approach Intelligence Ventures emphasizes conviction and persistence as core organizational values. Despite being told repeatedly to abandon the fund concept during its two-year formation period from 2021 to 2023, Nissinoff doubled down after recognizing ChatGPT's explosive adoption. The fund explicitly rejects companies simply "slapping AI labels" on traditional healthcare businesses. Instead, Intelligence Ventures seeks founders with rare combinations of technical brilliance and personal conviction about solving specific healthcare problems. Ideal founders demonstrate deep healthcare domain expertise combined with AI and machine learning fluency, understand regulatory pathways and commercialization requirements, and can articulate the specific, solvable healthcare problems they address. The fund views itself as building not just a portfolio but an entire ecosystem around AI-powered healthcare innovation, evidenced by quarterly HealthAI Pitch Showcases attracting 250 to 300+ investors, industry leaders, and strategic partners seeking exposure to early-stage healthcare AI companies.